↓ Skip to main content

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

Overview of attention for article published in Journal of Translational Medicine, January 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

patent
1 patent
wikipedia
1 Wikipedia page

Citations

dimensions_citation
97 Dimensions

Readers on

mendeley
148 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
Published in
Journal of Translational Medicine, January 2012
DOI 10.1186/1479-5876-10-169
Pubmed ID
Authors

Eva Ellebaek, Trine Iversen, Niels Junker, Marco Donia, Lotte Engell-Noerregaard, Özcan Met, Lisbet Hölmich, Rikke Andersen, Sine Hadrup, Mads Andersen, Per thor Straten, Inge Svane

Abstract

Adoptive cell therapy may be based on isolation of tumor-specific T cells, e.g. autologous tumor infiltrating lymphocytes (TIL), in vitro activation and expansion and the reinfusion of these cells into patients upon chemotherapy induced lymphodepletion. Together with high-dose interleukin (IL)-2 this treatment has been given to patients with advanced malignant melanoma and impressive response rates but also significant IL-2 associated toxicity have been observed. Here we present data from a feasibility study at a Danish Translational Research Center using TIL adoptive transfer in combination with low-dose subcutaneous IL-2 injections.

Mendeley readers

The data shown below were compiled from readership statistics for 148 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 <1%
Denmark 1 <1%
France 1 <1%
Unknown 145 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 31 21%
Student > Ph. D. Student 31 21%
Student > Master 26 18%
Student > Bachelor 15 10%
Other 10 7%
Other 16 11%
Unknown 19 13%
Readers by discipline Count As %
Medicine and Dentistry 45 30%
Agricultural and Biological Sciences 44 30%
Biochemistry, Genetics and Molecular Biology 15 10%
Immunology and Microbiology 15 10%
Pharmacology, Toxicology and Pharmaceutical Science 3 2%
Other 6 4%
Unknown 20 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 April 2019.
All research outputs
#2,829,651
of 14,795,345 outputs
Outputs from Journal of Translational Medicine
#406
of 2,826 outputs
Outputs of similar age
#55,955
of 284,113 outputs
Outputs of similar age from Journal of Translational Medicine
#13
of 101 outputs
Altmetric has tracked 14,795,345 research outputs across all sources so far. Compared to these this one has done well and is in the 77th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,826 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 284,113 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 101 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.